A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar) In HBV (+) Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 17 Apr 2025
At a glance
- Drugs KD 018 (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms CALM
- Sponsors Yiviva
- 13 Apr 2025 Status changed from active, no longer recruiting to completed.
- 05 Feb 2024 According to a Yiviva media release, the company is expecting a data readout in 2024.
- 05 Feb 2024 Status changed from recruiting to active, no longer recruiting.